Roche’s gantenerumab has failed to make the grade in its GRADUATE studies, leaving the field wide open for Eisai and Biogen’s lecanemab.

Roche's pharma revenues declined in the third quarter, but the Swiss major is hoping that Tecentriq in adjuvant settings can boost future revenues – and that, just maybe, it will have a win from its Alzheimer’s candidate too.

Biogen and Happy Health announced a pilot partnership to evaluate Happify Health’s Kopa app to support people living with multiple sclerosis. This follows a licensing deal with digital therapeutics developer MedRhythms to support MS patients with gait deficit.

The ambitious prevention study in people with a nearly 100% chance of developing Alzheimer’s disease has failed, and attention will now switch to trial readouts for the next generation of beta-amyloid targeting candidates.